[{"orgOrder":0,"company":"Sami-Sabinsa Group","sponsor":"Postbiotics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sami-Sabinsa Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sami-Sabinsa Group \/ Postbiotics","highestDevelopmentStatusID":"15","companyTruncated":"Sami-Sabinsa Group \/ Postbiotics"}]

Find Clinical Drug Pipeline Developments & Deals by Sami-Sabinsa Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The distribution agreement aims for the dietary supplement and functional food ingredient PoZibio for age-related digestive health conditions including Leaky Gut Syndrome (LGS).

                          Product Name : PoZibio

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          October 23, 2024

                          Lead Product(s) : Lactobacillus Paracasei

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Postbiotics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank